Olaparib 300mg tablets
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Newly Diagnosed
Conditions
Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation, Complete Response, Partial Response, First Line Platinum Chemotherapy
Trial Timeline
Aug 26, 2013 → Aug 29, 2028
NCT ID
NCT01844986About Olaparib 300mg tablets
Olaparib 300mg tablets is a phase 3 stage product being developed by AstraZeneca for Newly Diagnosed. The current trial status is active. This product is registered under clinical trial identifier NCT01844986. Target conditions include Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03534453 | Phase 3 | Completed |
| NCT01844986 | Phase 3 | Active |
Competing Products
18 competing products in Newly Diagnosed